Tirzepatide is a newer GLP-1 receptor agonist with one additional mechanism that separates it from semaglutide: it also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). This dual action — GLP-1 plus GIP — produces meaningfully greater weight loss in clinical trials. For patients evaluating medical weight management, understanding the difference matters.

How Tirzepatide Differs from Semaglutide

Both medications are GLP-1 receptor agonists — they reduce appetite, slow gastric emptying, and improve insulin sensitivity. Tirzepatide additionally activates the GIP receptor, which:

Want to talk it through with our team?

Book a free 15-minute video consult. Start for $247 — includes your first doctor visit. No membership.

How it works, step by step · See medication prices

The practical result: tirzepatide consistently produces 3–5 percentage points more weight loss than semaglutide in head-to-head comparisons.

Clinical Trial Data: Head-to-Head Comparison

Medication Trial Duration Average Weight Loss Top Quartile
Semaglutide 2.4 mg STEP 1 68 weeks 14.9% body weight ~24%
Tirzepatide 15 mg SURMOUNT-1 72 weeks 20.9% body weight ~35%
Tirzepatide vs Semaglutide SURMOUNT-5 (2024) 72 weeks Tirzepatide: 20.2% / Semaglutide: 13.7% Tirzepatide wins by ~6.5 pts

In SURMOUNT-5 — the first direct head-to-head trial — tirzepatide produced 47% more relative weight loss than semaglutide. Approximately twice as many tirzepatide patients achieved 25%+ body weight loss.

Side Effect Comparison

Both medications share the same GI side effect profile: nausea, reduced appetite, constipation, and occasional vomiting — particularly during dose escalation. These are generally manageable and resolve with dose adaptation. No clinically meaningful difference in side effect rates between the two medications has been established, though individual responses vary.

Dosing and Titration

Tirzepatide (weekly subcutaneous injection):

Semaglutide (weekly subcutaneous injection):

Which to Choose?

For most patients starting medical weight loss without a specific contraindication to either medication, tirzepatide’s clinical superiority makes it the preferred first choice based on current evidence. Situations where semaglutide may be preferred:

Both medications require the same medical oversight — comprehensive lab evaluation before starting, follow-up monitoring, and provider-managed dose titration.

The Hormone Factor in Both Medications

Both tirzepatide and semaglutide produce significantly better results when hormonal barriers to weight loss are addressed in parallel. A patient with untreated hypothyroidism or testosterone deficiency will underperform on either medication. MultiGen Wellness evaluates the full hormone and metabolic picture before initiating any GLP-1 program.

MultiGen Wellness provides physician-supervised GLP-1 programs including both semaglutide and tirzepatide. We evaluate your complete metabolic picture before recommending the right medication. Use the form below.

How it works

From your first call to medication at your door.

  1. A
    Free 15-minute video consult. We go over your goals, answer your questions, and confirm we can treat you in your state.
  2. B
    Start for $247, which includes your first doctor visit.
  3. C
    Lab work: free with insurance at Quest or any other lab. Book your Quest visit in your patient portal, or take our lab order form to any lab that takes your insurance.
  4. D
    Doctor visit: once results are back, meet by video with a dedicated hormone therapy specialist (PAs, NPs and doctors on staff) to review labs and plan medication or therapy.
  5. E
    Medication shipped to your door. We bill you for the medication and ship it to your house. See medication prices

What it costs

  • No monthly fee, no membership, no commitment.
  • $97 per visit, only when needed.
  • Prescriptions need lab work and a video visit at least every 90 days.
  • Most new patients are seen every 30 days at first.

See the full How It Works page

📞 1-800-259-0015 Sign Up Book Free Consult Patient Portal